Overview

Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301

Status:
SUSPENDED
Trial end date:
2026-03-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the efficacy and safety of CTx-1301 in children (6-12) with ADHD in a laboratory classroom setting.
Phase:
PHASE3
Details
Lead Sponsor:
Cingulate Therapeutics
Treatments:
Dexmethylphenidate Hydrochloride